CureVac Reports Q1 2025 Financial Results Amid Revenue Decline

CureVac ( (CVAC) ) just unveiled an update.

CureVac N.V. reported its financial results for the first quarter of 2025, revealing a net loss of €52.1 million, an improvement from the €70.6 million loss in the same period of 2024. Despite a significant drop in revenue from €12.4 million in 2024 to €0.9 million in 2025, the company managed to reduce its operating loss from €73.3 million to €54.7 million, reflecting cost management and operational adjustments. These financial results highlight the ongoing challenges CureVac faces in its market positioning and the implications for stakeholders as the company navigates its strategic initiatives.

The most recent analyst rating on (CVAC) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.

Spark’s Take on CVAC Stock

According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.

CureVac’s overall score reflects a company with substantial financial improvements, attractive valuation, and strategic partnerships, particularly with GSK. The strong cash position and advancements in oncology are positive indicators. However, past volatility in financial performance and operational challenges like restructuring costs remain concerns. The technical indicators suggest moderate positive momentum, enhancing the stock’s attractiveness for investors.

To see Spark’s full report on CVAC stock, click here.

More about CureVac

CureVac N.V. is a biotechnology company based in Tübingen, Germany, focusing on the development of mRNA-based therapies and vaccines. The company is engaged in the biopharmaceutical industry, with a primary emphasis on innovative solutions for infectious diseases and cancer.

Average Trading Volume: 619,653

Technical Sentiment Signal: Buy

Current Market Cap: $871.4M

For detailed information about CVAC stock, go to TipRanks’ Stock Analysis page.